Free Trial

Nyxoah Q2 2023 Earnings Report

Nyxoah logo
$7.96 -0.05 (-0.62%)
(As of 11:01 AM ET)

Nyxoah EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.45
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
$1.21 million
Expected Revenue
$1.04 million
Beat/Miss
Beat by +$170.00 thousand
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Cackling Kamala hates this company (Ad)

Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.

Nyxoah Earnings Headlines

Publication relating to transparency notifications
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Nyxoah's (NYXH) "Buy" Rating Reiterated at HC Wainwright
Nyxoah’s Strategic Expansion and Market Potential Drive Buy Rating
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

View Nyxoah Profile

More Earnings Resources from MarketBeat

Upcoming Earnings